This technology provides methods for treating disorders involving low bone mass by administering tryptophan hydroxylase (TPH1) inhibitors or serotonin receptor antagonists to control serum serotonin levels.
Serotonin is implicated in a wide gamut of bodily functions, including regulating bone mass. However, current methods of producing serotonin inhibitors are limited and many drugs that modulate serotonin levels lead to adverse side effects. Given these limitations, development of serotonin inhibitors or modulators in the context of bone disorders has been severely restricted.
This technology utilizes TPH1 inhibitors and serotonin receptor antagonists to treat various bone disorders by controlling serotonin levels. By administering these therapeutic agents for lowering or increasing serum serotonin levels, bone mass can be increased or decreased. Furthermore, these compounds are highly effective at suppressing peripheral serotonin levels without any effect on central nervous system levels of serotonin, which mitigates adverse effects. As a result, these compounds offer effective potential therapeutics for treating bone disorders such as osteoporosis.
IR 2497
Licensing Contact: Jerry Kokoshka